Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

An Oxford University researcher has been awarded nearly £1m from Cancer Research UK to investigate a new form of treatment for prostate cancer.

© NDS

Dr Richard Bryant, a urological surgeon and clinical lecturer at Oxford University’s Nuffield Department of Surgical Sciences, will use the cash injection to investigate combining a new form of treatment alongside conventional radiotherapy for men with advanced or aggressive forms of prostate cancer.

If his research proves to be both safe and effective for patients, Dr Bryant believes it could be 'game-changing' for men diagnosed with the disease in the future.

Dr Bryant was awarded a Clinician Scientist Fellowship, which supports cancer doctors carrying out research. He will receive £847,242 over five years to carry out his research in the hope of transforming treatments for future prostate cancer patients.

His project will look at the use of vascular-targeted photodynamic therapy (VTP) – a novel form of minimally invasive surgery that uses light treatment to target the destruction of a specific area of tissue such as a tumour while limiting any potential damage to healthy tissue – in combination with radiotherapy. The aim is to establish if the combined VTP and radiotherapy treatment is more effective than each treatment given alone.

Prostate cancer is the commonest cancer in men in the United Kingdom and around 500 men are diagnosed in Oxfordshire every year.

Many patients currently receive a course of radiotherapy, which is delivered over approximately six weeks. Many of these patients will be cured by radiotherapy, but in some patients the cancer can return, and in addition to this the radiotherapy itself can have significant side effects.

It is highly exciting research and I feel that this could be a potential game-changer for radiotherapy treatment for men with prostate cancer   - Dr Richard Bryant

The new form of light treatment, or VTP, damages the blood vessels and ‘starves tumours’ thereby destroying them. It has recently been tested in clinical trials for patients with very low-risk and low-volume early-stage prostate cancer and has been demonstrated to be safe and effective in those individuals, but it has not yet been used in combination with another treatment such as radiotherapy, nor has it used to treat more aggressive or advanced prostate cancer.

Dr Bryant said: 'Radiotherapy can cure many cases of prostate cancer, but it can cause difficult side effects and it may not be able to successfully treat some patients – possibly because the cancer has already spread or because some patients have a particularly aggressive form of the disease.

'We know that radiotherapy can still be improved and this is where I hope that this project takes us. We want to see if we can combine radiotherapy with another novel treatment. If we can show that this is safe and achievable then it could lead to a reduction in the necessary radiotherapy dose currently given to men with prostate cancer, thereby reducing the side effects of treatment.'

He added: 'It is highly exciting research and I feel that this could be a potential game-changer for radiotherapy treatment for men with prostate cancer. My hope is that it could lead to a step-change in the delivery of modern radiotherapy with the addition of a minimally invasive form of targeted surgery, and my aim would be to have early-phase clinical trials in patients within five years.'

Dr Karen Noble, head of research training and fellowships at Cancer Research UK, said: 'These awards allow us to support talented clinicians who will become the next generation of leaders in cancer research. They help encourage clinicians to continue to carry out vital research in conjunction with their clinical work treating patients

'This exciting piece of work which the Clinical Careers Committee has chosen to fund will discover if a new approach to the treatment of prostate cancer works well – and most importantly is safe – in patients.'

 

Read the story in the Oxford Mail.

Similar stories

Professor Peter McCulloch receives NIHR Senior Investigator Award

Awards and appointments

We are delighted to announce that Professor Peter McCulloch of the Nuffield Department of Surgical Sciences has been awarded the title of NIHR Senior Investigator.

New Cochrane evidence explores treatment options for chronic ear disease

Publication Research

A new Evidently Cochrane blog post for World Hearing Day summarises seven recent reviews on medical treatments for infection and inflammation of the middle ear.

New reporting guidelines to bridge the gap from development to implementation in clinical artificial intelligence

Innovation Research

In a correspondence to Nature Medicine, a team of Oxford-led academics describe upcoming new guidelines to improve the reporting of early clinical stage (or first-with-human) evaluation of decision support systems driven by artificial intelligence.

NDS project awarded Public Engagement Seed Funding 2020-21

Awards and appointments Public engagement

Seven projects from the Medical Sciences Division, including a project from the Nuffield Department of Surgical Sciences, have received funding in the 2020-21 round of the Public Engagement with Research Seed Fund for innovative projects to engage the public with medical research.

Cochrane ENT awarded NIHR funding for COVID-19 project

Awards and appointments Coronavirus COVID-19 Research

Cochrane ENT at the Nuffield Department of Surgical Sciences has been awarded funding by the National Institute for Health Research (NIHR) to complete a suite of living systematic reviews investigating the effectiveness and safety of interventions to prevent and treat loss of smell after COVID-19 infection.

First peer-reviewed results of phase 3 human trials of Oxford coronavirus vaccine demonstrate efficacy

Coronavirus COVID-19 Publication Research

Today University of Oxford and AstraZeneca researchers present a pooled analysis of Phase 3 trials of a vaccine against SARS-CoV-2 across two different dose regimens, resulting in an average efficacy of 70.4%.